Skip to content
10-Q

Quarterly Report

ALZAMEND NEURO, INC. ALZN

0001214659-25-013609

← back to feed
Filed
Sep 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Sep 10, 2025 3.14M sh
Shares Diluted Q1 2026 · Jul 31, 2025 2.11M sh
Shares Diluted restated Q1 2026 · Jul 31, 2024 85.31K sh
Operating Cash Flow Q1 2026 · Jul 31, 2025 −$2.36M
Operating Cash Flow Q1 2026 · Jul 31, 2024 −$1.06M
Cash And Equivalents Q1 2026 · Jul 31, 2025 $5.62M
Cash And Equivalents Q1 2026 · Apr 30, 2025 $3.95M
Stockholders Equity Q1 2026 · Jul 31, 2025 $5.34M
Stockholders Equity Q1 2026 · Apr 30, 2025 $3.97M
Stockholders Equity Q1 2026 · Jul 31, 2024 −$1.21M
Stockholders Equity Q1 2026 · Apr 30, 2024 −$2.59M
Total Liabilities Q1 2026 · Jul 31, 2025 $983.31K
Total Liabilities Q1 2026 · Apr 30, 2025 $634.76K
Current Assets Q1 2026 · Jul 31, 2025 $5.93M
Current Assets Q1 2026 · Apr 30, 2025 $4.18M
Total Assets Q1 2026 · Jul 31, 2025 $6.33M
Total Assets Q1 2026 · Apr 30, 2025 $4.6M
Eps Diluted Q1 2026 · Jul 31, 2025 −$1.28
Eps Diluted restated Q1 2026 · Jul 31, 2024 −$11.42
Eps Basic Q1 2026 · Jul 31, 2025 −$1.28
Eps Basic restated Q1 2026 · Jul 31, 2024 −$11.42
Sga Expense Q1 2026 · Jul 31, 2025 $959.33K
Sga Expense Q1 2026 · Jul 31, 2024 $755.83K
Rd Expense Q1 2026 · Jul 31, 2025 $1.74M
Rd Expense Q1 2026 · Jul 31, 2024 $206.57K
Net Income Q1 2026 · Jul 31, 2025 −$2.7M
Net Income Q1 2026 · Jul 31, 2024 −$974.41K
Operating Income Q1 2026 · Jul 31, 2025 −$2.7M
Operating Income Q1 2026 · Jul 31, 2024 −$962.41K